IKE Capital’s Biogen BIIB Stock Holding History

IKE Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$604K	Sell	2,794 -400	-13%	-$76.5K	0.32%	62
2026 Q1	$586K	Hold	3,194	–	–	0.33%	67
2025 Q4	$562K	Buy	+3,194	New	+$522K	0.49%	53

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IKE Capital's BIIB Position: Q2 2026 in Review

IKE Capital reduced its Biogen (BIIB) stake by 13% in Q2 2026, selling an estimated $76.5K and leaving 2,794 shares worth $604K. The position accounts for 0.32% of the portfolio, ranked #62.

IKE Capital first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

IKE Capital held 2,794 shares of Biogen worth $604K as of Q2 2026.
IKE Capital sold 400 Biogen shares in Q2 2026, an estimated $76.5K.
Biogen made up 0.32% of IKE Capital's portfolio in Q2 2026, its #62 holding.
IKE Capital first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on IKE Capital's 13F filing for Q2 2026, filed 16 Sep 2026.